C WorldWide Group Holding A S decreased its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 10.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 342,894 shares of the biopharmaceutical company’s stock after selling 40,254 shares during the quarter. C WorldWide Group Holding A S’s holdings in Horizon Pharma were worth $5,006,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Advantage Investment Management LLC lifted its position in Horizon Pharma by 164.8% in the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,900 shares in the last quarter. Family Management Corp purchased a new stake in Horizon Pharma in the 2nd quarter worth approximately $131,000. Brown Advisory Inc. purchased a new stake in Horizon Pharma in the 3rd quarter worth approximately $145,000. Prudential Financial Inc. lifted its position in Horizon Pharma by 5.0% in the 2nd quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 830 shares in the last quarter. Finally, Fox Run Management L.L.C. lifted its position in Horizon Pharma by 21.5% in the 4th quarter. Fox Run Management L.L.C. now owns 19,200 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 3,400 shares in the last quarter. Institutional investors own 85.95% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Monday, January 8th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Horizon Pharma in a research report on Sunday, October 22nd. ValuEngine upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Monday, October 16th. UBS Group set a $20.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, November 30th. Finally, BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. Horizon Pharma has an average rating of “Buy” and a consensus price target of $19.25.

Horizon Pharma PLC (NASDAQ:HZNP) opened at $13.76 on Friday. The firm has a market cap of $2,210.00, a price-to-earnings ratio of -4.53, a PEG ratio of 0.66 and a beta of 1.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. Horizon Pharma PLC has a twelve month low of $9.45 and a twelve month high of $17.69.

WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/horizon-pharma-plc-hznp-shares-sold-by-c-worldwide-group-holding-a-s/1856617.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.